Telix Pharmaceuticals (TLX) Non-Current Debt (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Non-Current Debt for 3 consecutive years, with $391.9 million the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Debt rose 0.57% year-over-year to $391.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $391.9 million (up 0.57% YoY) and the FY2025 annual result came in at $391.9 million, up 14.66% from the prior year.
• Non-Current Debt improved to $391.9 million in Q4 2025 per TLX's latest filing, from $389.7 million in the prior quarter.
• Over the last five years, Non-Current Debt for TLX reached as high as $391.9 million in Q4 2025 and fell as low as $5.8 million in Q4 2023.
• A 3-year average of $262.5 million and a median of $389.7 million in 2024 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2024 — Non-Current Debt soared 6622.15% — and 2025, when it rose 0.57%.
• Year by year, Non-Current Debt stood at $5.8 million in 2023, then surged by 6622.15% to $389.7 million in 2024, then climbed by 0.57% to $391.9 million in 2025.
• According to Business Quant data, Non-Current Debt over the past three periods registered $391.9 million, $389.7 million, and $5.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.